Pharming Group (NASDAQ:PHAR - Get Free Report) saw unusually-high trading volume on Wednesday . Approximately 6,598 shares traded hands during trading, an increase of 7% from the previous session's volume of 6,182 shares.The stock last traded at $8.80 and had previously closed at $8.80.
Analysts Set New Price Targets
A number of research firms have weighed in on PHAR. Jefferies Financial Group started coverage on Pharming Group in a research note on Monday, December 9th. They issued a "buy" rating and a $14.00 price target on the stock. HC Wainwright reiterated a "buy" rating and set a $37.00 price target on shares of Pharming Group in a research note on Thursday. Finally, Oppenheimer boosted their price target on shares of Pharming Group from $30.00 to $39.00 and gave the stock an "outperform" rating in a research note on Friday, March 14th.
Check Out Our Latest Stock Report on PHAR
Pharming Group Stock Performance
The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $605.75 million, a price-to-earnings ratio of -34.25 and a beta of -0.10. The stock has a 50-day simple moving average of $8.90 and a 200-day simple moving average of $8.63.
Pharming Group (NASDAQ:PHAR - Get Free Report) last announced its earnings results on Thursday, March 13th. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.02). Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. The firm had revenue of $92.70 million for the quarter, compared to the consensus estimate of $76.67 million. On average, analysts anticipate that Pharming Group will post -0.2 earnings per share for the current year.
Institutional Investors Weigh In On Pharming Group
A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its holdings in Pharming Group (NASDAQ:PHAR - Free Report) by 16.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 47,997 shares of the company's stock after purchasing an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned about 0.07% of Pharming Group worth $483,000 as of its most recent filing with the SEC. 0.03% of the stock is owned by hedge funds and other institutional investors.
Pharming Group Company Profile
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Recommended Stories
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
